Schizophrenia: Market Potential of Zyprexa Depot

A Survey of Fifty Psychiatrists

April 2007

Study Description

Topic	Zyprexa Depot and the Atypical Antipsychotics Market
Respondent Type	Physicians
Specialties Covered	Psychiatry
Region	United States Only
Methodology	§       Self-administered survey §       Approximately 20 minutes duration §       50 total respondents §       Fielded online from April 6, 2007 to April 9, 2007

Objectives

§    Evaluate current use of atypical and typical antipsychotics among patients with schizophrenia or bipolar disorder

§    Assess the current market for long-acting injectable antipsychotics

§    Gauge the degree to which current prescribers of oral Zyprexa will convert to prescribing Zyprexa Depot

§    Determine expected future prescribing volumes for atypical and typical antipsychotics

Companies and Products Mentioned in This Report 

Company	Ticker Symbol	Product(s)
Eli Lilly	LLY	Zyprexa Depot Zyprexa
AstraZeneca	AZN	Seroquel
Janssen		Risperdal Oral Risperdal Consta

Respondent Demographics

§    50 board-certified or board-eligible psychiatrists, 96% general, 4% geriatric §    Currently managing an average of 108.5 schizophrenia patients and 135.3 bipolar patients §    Mean 15.4 years in practice §    Mean 94% of professional time in clinical practice